Tadalafil Tablet
Product Images NDC 68071-3540

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3540). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3540 3)

Label for Tadalafil 2.5 mg tablets by NuCare Pharmaceuticals, Inc. The label indicates a 30-tablet count. It includes manufacturer details as Ajanta Pharma Limited, Mumbai, and packaging info by NuCare Pharmaceuticals, Inc., Orange, CA. The label shows barcodes, product number R1942025, and storage instructions to keep at controlled temperature 68-77°F. It carries warnings to keep out of reach of children and advises consulting a doctor for side effects.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph showing the change from baseline in IPSS Total Score over a 12-week treatment period. Two lines represent Tadalafil 5 mg and placebo, with Tadalafil showing a greater decrease in score over time compared to placebo. The x-axis is labeled 'Duration of Treatment (weeks)' and the y-axis 'Change from Baseline in IPSS Total Score.' A statistical significance marker (* p<0.01) is indicated at 12 weeks.*

FDA Label Image

Figure1 (Tadalafil Figure1)

Four line graphs depicting the difference in blood pressure (mmHg) over time (hours) between tadalafil and placebo. The graphs show changes in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure across a 0 to 96-hour period, with error bars representing variability.*

FDA Label Image

Figure2 (Tadalafil Figure2)

This figure presents two graphs depicting standing and supine systolic blood pressure changes over 24 hours post-dose. The top graph shows standing systolic blood pressure (mmHg) versus time (hours), comparing Tadalafil 20 mg plus doxazosin 8 mg to placebo plus doxazosin 8 mg. The bottom graph shows supine systolic blood pressure changes similarly over time.*

FDA Label Image

Figure3 (Tadalafil Figure3)

Line graph depicting systolic blood pressure (BP) changes over 12 hours following administration of tadalafil or placebo combined with doxazosin. Four treatment groups are shown, each with different dosing times of tadalafil (8:00 or 20:00) and consistent doxazosin dosing. The y-axis shows systolic BP changes in mmHg, and the x-axis shows time after administration in hours.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dosing following 5 consecutive days. The graph shows concentration changes from 0 to 120 hours with error bars indicating variability.*

FDA Label Image

Figure5 (Tadalafil Figure5)

Line graph comparing the change from baseline in IPSS total score over a 12-week treatment period between Tadalafil 5 mg and placebo groups. The x-axis shows duration of treatment in weeks, and the y-axis shows change in IPSS score, with Tadalafil showing a greater decrease. Statistical significance (p<0.01) is indicated.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS Total Score over a 12-week treatment period for Tadalafil 5 mg versus placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline. The graph indicates statistically significant differences marked with an asterisk for Tadalafil at certain time points.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph titled 'Weeks of Therapy' showing least-squares mean change from baseline over 26 weeks for two groups: Tadalafil/Finasteride and Placebo/Finasteride. The y-axis measures change from baseline, with data points at 0, 12, and 26 weeks. Tadalafil/Finasteride shows greater negative changes compared to Placebo/Finasteride at weeks 12 and 26, with statistical significance indicated by symbols for p<0.001 and p<0.05.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure diagram of Tadalafil, showing its multi-ring molecular arrangement including a piperazine ring and a fused bicyclic system.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.